Free Trial

Fennec Pharmaceuticals Q1 2024 Earnings Report

Fennec Pharmaceuticals logo
C$8.67 +0.16 (+1.88%)
(As of 12/17/2024 ET)

Fennec Pharmaceuticals EPS Results

Actual EPS
C$0.56
Consensus EPS
C$0.67
Beat/Miss
Missed by -C$0.11
One Year Ago EPS
N/A

Fennec Pharmaceuticals Revenue Results

Actual Revenue
$34.21 million
Expected Revenue
$14.19 million
Beat/Miss
Beat by +$20.02 million
YoY Revenue Growth
N/A

Fennec Pharmaceuticals Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Hiding in the Bible (Ad)

New documentary reveals the lost wealth-building secret hidden deep within ancient religious texts from almost every civilization… an investment one expert says is “so perfect that only God could have created it.” Watch it now to discover how this asset that you’ve likely never considered before can produce returns so safe, secure, and endless it is nothing short of miraculous.

This is the untold, true story of God’s Investment.

Fennec Pharmaceuticals Earnings Headlines

Fennec Pharmaceuticals (FENC) Gets a Buy from Craig-Hallum
Do this Before Elon’s Reveal on January 22nd
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
Fennec announces three executive appointments
Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc (FRX)
See More Fennec Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fennec Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fennec Pharmaceuticals and other key companies, straight to your email.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals (TSE:FRX) operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

View Fennec Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings